ADAsaf Danon

Asaf Danon

*This is an algorithmically generated author record based on publicly available information.

Asaf Danon has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Human Factor: Physicians’ Unbiased Interpretation of Atrial Fibrillation in the Emergency Department

    by Yuval Avidan, Razi Khoury, Hani Sliman, Sameha Zahra, Asaf Danon, Sameer Kassem

    Background: Misinterpretation of atrial fibrillation (AF) poses significant clinical risks. While the impact of computerized ECG interpretations (CIE) on clinical decision‐making is well‐documented, there is limited real‐world evidence on the diagnostic accuracy of emergency department (ED) clinicians in the absence of such tools. This study examines the frequency and clinical impact of AF misdiagnosis in an ED operating without CIE. Methods: ECGs of consecutive patients discharged with a diagnosis of AF over a five‐year period were reevaluated by two cardiologists, with an electrophysiologist serving as an arbitrator. Misdiagnosed cases underwent further clinical follow‐up. Results: Of 1828 ECGs initially identified as AF, 31 were excluded due to paced rhythms or indeterminate tracings, yielding a final cohort of 1797. Among these, 49 cases (2.7%) were misclassified, encompassing supraventricular tachycardia ( n = 30), sinus rhythm with premature atrial contractions, Mobitz type I block, or artifact ( n = 18), and multifocal atrial tachycardia ( n = 1). Patients with erroneous AF diagnoses were older (mean age 76.7 vs. 72.5 years, p = 0.032) and frequently received inappropriate therapies, including rate‐control agents ( n = 12), antiarrhythmics ( n = 8), and anticoagulants ( n = 24). Conclusions: AF misdiagnosis remains prevalent in the ED and can lead to unnecessary pharmacotherapy. The misdiagnosis rate appears comparable between CIE‐assisted and physician‐only interpretations.

  • Open Access

    Trends in the Incidence of Cardiovascular Diagnoses and Procedures over the Years 2012–2021 in Israel: The Impact of the COVID-19 Pandemic

    by Orna Reges, Wiessam Abu Ahmad, Erez Battat, Walid Saliba, Yael Wolff Sagy, Asaf Danon, Gil Lavie

    Prior studies found reduced incidences of cardiovascular diagnoses and treatments in the initial phase of the COVID-19 pandemic. However, these studies included a limited number of outcomes and did not consider pre-pandemic trends. This study aimed to describe trends in the incidence of cardiovascular diagnoses and treatments over the years 2012–2021 in Israel and to compare the two years of the COVID-19 period with the preceding 8 years. In this retrospective, population-based study, carried out within Clalit Health Services, the incidence rates of cardiovascular outcomes were calculated for individuals aged ≥ 25 (~2.7 million adults per year) during the first (Y1, 3/2020–2/2021) and second (Y2, 3/2021–2/2022) years of COVID-19 and the 8 years prior (3/2012–2/2020). Declines were observed in Y1 compared to 2019 in all diagnoses and treatments: STEMI (−16.3%; 95% CI: −16.6, −16.1), non-STEMI (−16.4%; −16.6, −16.2), AF (−14.1%; −14.2, −14.0), CHF (−7.8%; −7.9, −7.7), CVA (−5.0%; −5.0, −4.9), catheterization (−64.7%; −65.2, −64.2), CABG (−77.7%; −79.2, −76.2), ablation (−21.2%; −22.0, −20.4), pacemaker implantation (−39.3%; −40.7, −37.9), and defibrillator insertion (−12.5%; −13.1, −12.0). Compared with expected rates based on pre-pandemic trends, observed rates were within expected ranges (CHF, CVA, and ablation), less than expected (STEMI, non-STEMI, AF, catheterization, CABG, and pacemaker insertion), or more than expected (defibrillator insertion). In Y2, STEMI, catheterization, and CABG returned to expected rates; non-STEMI and AF were lower than expected; and CHF, CVA, ablation, and pacemaker and defibrillator implantations were higher than expected. Several cardiovascular diagnoses and treatment trends were interrupted by COVID-19. The long-term consequences of these changes should be considered by health policymakers.

  • Open Access

    Direct Admission of Patients With ST‐Segment–Elevation Myocardial Infarction to the Catheterization Laboratory Shortens Pain‐to‐Balloon and Door‐to‐Balloon Time Intervals but Only the Pain‐to‐Balloon Interval Impacts Short‐ and Long‐Term Mortality

    by Simcha R. Meisel, Michael Kleiner‐Shochat, Rami Abu‐Fanne, Aaron Frimerman, Asaf Danon, Sa’aR Minha, Yaniv Levi, Alex Blatt, Jameel Mohsen, Avraham Shotan, et al.

    Background: Shortening the pain‐to‐balloon (P2B) and door‐to‐balloon (D2B) intervals in patients with ST‐segment–elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PPCI) is essential in order to limit myocardial damage. We investigated whether direct admission of PPCI‐treated patients with STEMI to the catheterization laboratory, bypassing the emergency department, expedites reperfusion and improves prognosis. Methods and Results: Consecutive PPCI‐treated patients with STEMI included in the ACSIS (Acute Coronary Syndrome in Israel Survey), a prospective nationwide multicenter registry, were divided into patients admitted directly or via the emergency department. The impact of the P2B and D2B intervals on mortality was compared between groups by logistic regression and propensity score matching. Of the 4839 PPCI‐treated patients with STEMI, 1174 were admitted directly and 3665 via the emergency department. Respective median P2B and D2B were shorter among the directly admitted patients with STEMI (160 and 35 minutes) compared with those admitted via the emergency department (210 and 75 minutes, P P P <0.001). Conclusions: Direct admission of PPCI‐treated patients with STEMI decreased mortality by shortening P2B and D2B intervals considerably. However, P2B, but not D2B, impacted mortality. It seems that the D2B interval has reached its limit of effect. Thus, all efforts should be extended to shorten P2B by educating the public to activate early the emergency medical services to bypass the emergency department and allow timely PPCI for the best outcome.


  • Safety and Efficacy of Dabigatran Compared With Warfarin for Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-analysis

    by Mohammed Shurrab, Carlos A. Morillo, Sam Schulman, Nitin Kansal, Asaf Danon, David Newman, Ilan Lashevsky, Jeff S. Healey, Eugene Crystal